Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data

Cancer Management and Research - New Zealand
doi 10.2147/cmar.s219570
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Informa UK Limited

Related search

Prognosis and New Therapeutic Approaches in Chronic Lymphocytic Leukemia Treatment

Medicinski podmladak
2019English

Durvalumab for the Management of Urothelial Carcinoma: A Short Review on the Emerging Data and Therapeutic Potential

OncoTargets and Therapy
OncologyPharmacology
2019English

Acalabrutinib With Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: 3-Year Follow-Up

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

VENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (Literature Review)

Oncogematologiya
OncologyHematology
2018English

Refractory Chronic Lymphocytic Leukemia – New Therapeutic Strategies

Oncotarget
Oncology
2010English

Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Correction: Potential Therapeutic Application of Gold Nanoparticles in B-Chronic Lymphocytic Leukemia (BCLL): Enhancing Apoptosis

Journal of Nanobiotechnology
Applied MicrobiologyMolecular MedicineNanosciencePharmaceutical ScienceMedicineBiotechnologyBioengineeringBiomedical EngineeringNanotechnology
2013English

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia

ISRN Oncology
2014English

Nrf2 Responses and the Therapeutic Selectivity of Electrophilic Compounds in Chronic Lymphocytic Leukemia

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy